
Arif Sheikh MD
Clinical Professor Wright State University Chief of Nuclear Medicine: Division of Nuclear Medicine, Department of Radiology, Kettering Network Radiology, Inc. Medical Director Theranostics Program Kettering Health; Kettering, Ohio
Join to View Full Profile
Kettering Medical Center Nuclear Medicine / PET DepartmentRm# GNM0010 3535 Southern BlvdDayton, OH 45429
Phone+1 937-395-8611
Dr. Sheikh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Arif Sheikh is a Nuclear Medicine specialist based in Dayton, OH. He completed his medical education at Wayne State University School of Medicine and pursued residencies in Internal Medicine at Brown University and Nuclear Medicine at Memorial Sloan Kettering Cancer Center. Currently, he serves as Medical Director at Kettering Health Main Campus and Clinical Professor at Wright State University Boonshoft School of Medicine. Dr. Sheikh has held previous academic and clinical roles at Mount Sinai, Temple University, Columbia University, University of North Carolina Hospitals, and MedStar Franklin Square Medical Center. His experience encompasses nuclear cardiology, thyroid cancer, nuclear medicine, nuclear radiology, and molecular imaging. He has contributed to multiple publications, focusing on topics such as prostate cancer, rheumatoid arthritis, and blood quality for transfusion. Additionally, he has been involved in clinical trials, including studying treatment combinations for metastatic castration-resistant prostate cancer.
Education & Training
- Memorial Sloan Kettering Cancer CenterResidency, Nuclear Medicine, 1997 - 2002
- Rhode Island Hospital/Brown University HealthResidency, Internal Medicine, 1994 - 1997
- Wayne State University School of MedicineClass of 1994
Certifications & Licensure
- OH State Medical License 2020 - 2026
- IN State Medical License 2022 - 2025
- NY State Medical License 2003 - 2022
- PA State Medical License 2017 - 2018
- NC State Medical License 2004 - 2017
- DC State Medical License 2004 - 2010
- MD State Medical License 2003 - 2005
- American Board of Nuclear Medicine Nuclear Medicine
- Join now to see all
Clinical Trials
- Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer Start of enrollment: 2009 May 01
Publications & Presentations
PubMed
- 1 citationsArticularFluorodeoxyglucose Uptake Is Associated With Clinically Assessed Swollen Joint Count in Patients With Rheumatoid Arthritis.Iván Ferraz-Amaro, Arif Sheikh, Berna Polack, Jon T Giles, Joan M Bathon
The Journal of Rheumatology. 2022-12-01 - 29 citationsPhase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant ...Jaspreet S. Batra, Muhammad Junaid Niaz, Young E. Whang, Arif Sheikh, Charlene Thomas
Urologic Oncology. 2020-06-27 - 67 citationsDonor glucose-6-phosphate dehydrogenase deficiency decreases blood quality for transfusion.Richard O. Francis, Angelo D'Alessandro, Andrew Eisenberger, Mark Soffing, Randy Yeh
The Journal of Clinical Investigation. 2020-05-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: